This review looked at the economic value of using mismatch repair (MMR) status to guide immunotherapy for patients with advanced and recurrent endometrial cancer. The study focused on how testing helps determine the best treatment paths for different types of the disease.
Researchers found that patients with dMMR or MSI-H disease generally show the largest gains in quality-adjusted survival. These patients also showed the most favorable cost-effectiveness ratios when receiving immunotherapy. This suggests that MMR testing can help healthcare systems prioritize high-value treatments for those who need them most.
For patients with pMMR or MSS disease, the economic results were more sensitive to drug pricing and specific modeling assumptions. Because the evidence is based on a small review and some data points are still being refined, it is important to note that these findings are not yet used to change standard practice. Doctors can use MMR testing as a tool to help decide on the best treatment options for each individual patient.
